Fig. 3
A Expression levels of FASN differed between normal and tumor tissues and were correlated with PFI and OS of HCC patients. B IHC images of the tissue microarray stained with anti-FASN antibody. C IHC staining of FASN in HCC tumor tissue and adjacent tissue according to staining scores of the tissue microarray. D Kaplan–Meier survival curves of the correlation between FASN expression levels and overall survival according to the tissue microarray. E Enlarged IHC images of FASN staining from the tissue microarray. F The data were analyzed using a chi-square test. G and H FASN protein expression levels in parental and sorafenib-resistant cell lines. I CCK-8 assay of sensitivity to sorafenib in FASN-overexpressed Huh7 and 7721 cells versus control Huh7 and 7721 cells and IC50 values. J CCK-8 assay of the sensitivity to sorafenib of FASN-knock down Huh7SR and 7721SR cells and IC50 values. *p < 0.05; **p < 0.01; ***p < 0.001. sora, sorafenib; PFI, progressive-free interval; OS, overall survival; HCC, hepatocellular carcinoma